Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study

[1] Burstein HJ(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[2] Curigliano G(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[3] Loibl S(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352

[4] Burstein HJ(2019)Estimating the benefits of therapy for early stage breast cancer The St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Ann Oncol 30 1541-1557

[5] Lacchetti C(2019)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update J Clin Oncol 37 423-438

[6] Anderson H(2019)Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 30 1194-1220

[7] Cardoso F(2019)Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial J Clin Oncol 37 105-114

[8] Kyriakides S(2014)Adjuvant exemestane with ovarian suppression in premenopausal breast cancer N Engl J Med 371 107-108

[9] Ohno S(2018)Tailoring adjuvant endocrine therapy for premenopausal breast cancer N Engl J Med 379 122-137

[10] Ruhstaller T(2015)Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial J Clin Oncol 33 2772-2779

[1] Burstein HJ(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[2] Curigliano G(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[3] Loibl S(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352

[4] Burstein HJ(2019)Estimating the benefits of therapy for early stage breast cancer The St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Ann Oncol 30 1541-1557

[5] Lacchetti C(2019)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update J Clin Oncol 37 423-438

[6] Anderson H(2019)Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 30 1194-1220

[7] Cardoso F(2019)Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 trial J Clin Oncol 37 105-114

[8] Kyriakides S(2014)Adjuvant exemestane with ovarian suppression in premenopausal breast cancer N Engl J Med 371 107-108

[9] Ohno S(2018)Tailoring adjuvant endocrine therapy for premenopausal breast cancer N Engl J Med 379 122-137

[10] Ruhstaller T(2015)Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial J Clin Oncol 33 2772-2779